Andy Hsieh

Stock Analyst at William Blair

(0.04)
# 4,141
Out of 4,784 analysts
13
Total ratings
14.29%
Success rate
-27.01%
Average return

Stocks Rated by Andy Hsieh

Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.52
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.87
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $5.32
Upside: -
Terns Pharmaceuticals
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $2.92
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $19.77
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $3.82
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.38
Upside: -
Elevation Oncology
Jan 3, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.26
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.06
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $96.16
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $0.31
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $1.81
Upside: -